Myst Therapeutics, Inc. is a newly formed biotechnology company focused on the development and commercialization of novel broad spectrum cancer immunotherapy products designed to harness the power of a patient’s own immune system to destroy cancer cells. Myst is pursuing the development of an adoptive cell therapy utilizing enriched T cells from tumors and peripheral blood that target a broad spectrum of cancer mutations. Research at the National Cancer Institute and the successes of the checkpoint modulators has shown that the body’s own immune cells can recognize many different mutations in solid tumors. The problem is that those cells are often too weak to overcome the tumor. Myst plans to combine methods of identifying reactive T cells with state of the art techniques in cell sorting, T cell rejuvenation, and industry leading expertise in the development and manufacturing of cell therapies. Myst believes that combining these will enable the rapid advancement and commercialization these highly promising and innovative broad spectrum cancer therapies addressing a wide range of advanced solid tumors.